Anbio Biotechnology Class A Ordinary Shares
HealthcareNASDAQ:NNNN · NASDAQ Global Select
-$0.85 today
Vol 0.03M · Avg 0.03M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Earnings Waterfall
Revenue to Net Income
Key Ratios
Analysis
$18.6M of revenue converted into $9.7M of net income for the selected period. Gross margin is 81.3% and net margin is 39.0%, showing how much revenue survives after costs and taxes. EPS is $0.22, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $9.8M +19.2% | $8.2M +21.9% | $6.7M -71.5% | $23.5M +431.7% | $4.4M | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $1.2M -45.8% | $2.3M -31.4% | $3.4M -69.5% | $11.0M +482.1% | $1.9M | $725.6M | $804.0M | $882.4M |
| Gross Profit | $8.5M +44.6% | $5.9M +75.1% | $3.4M -73.2% | $12.6M +394.3% | $2.5M | $8.9B | $7.6B | $6.2B |
| Gross Margin | 87.2% +15.3pp | 71.9% +21.8pp | 50.1% -3.3pp | 53.4% -4.0pp | 57.4% | 9.8% | 28.9% | 38.3% |
| Research & Development | $227.2K -50.0% | $454.2K +237.2% | $134.7K -32.6% | $200.0K | $0 | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $1.8M -48.3% | $3.4M +171.6% | $1.3M -41.6% | $2.2M +2418.4% | $86.1K | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $2.0M -48.5% | $3.9M +177.9% | $1.4M -40.9% | $2.4M +2650.7% | $86.1K | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $0 | $0 -100.0% | $13.0K +108.5% | $6.3K | $0 | $374.2M | $1.2B | $631.8M |
| EBITDA | $6.5M +153.6% | $2.6M +13.2% | $2.3M -77.4% | $10.0M +295.4% | $2.5M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | 66.7% +35.3pp | 31.4% -2.4pp | 33.8% -8.8pp | 42.6% -14.7pp | 57.3% | 5.6% | 46.3% | 42.0% |
| Operating Income | $6.5M +226.2% | $2.0M +1.8% | $2.0M -80.8% | $10.2M +315.2% | $2.5M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | 66.7% +42.3pp | 24.4% -4.8pp | 29.2% -14.1pp | 43.3% -12.2pp | 55.5% | 16.6% | 24.1% | 22.0% |
| Interest Income | $160.3K -52.5% | $337.5K +104.1% | $165.3K +291.4% | $42.2K | $0 | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $0 | $0 | $0 -100.0% | $8.0K | $0 | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | $717.5K +90.1% | $377.5K +28.9% | $292.8K +258.8% | -$184.4K -330.7% | $79.9K | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | $7.2M +204.6% | $2.4M +5.3% | $2.3M -77.5% | $10.0M +294.8% | $2.5M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | 74.1% +45.1pp | 29.0% -4.6pp | 33.6% -8.9pp | 42.5% -14.7pp | 57.3% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 | $1.3B | -$1.6B | $745.2M |
| Net Income | $7.2M +204.6% | $2.4M +5.3% | $2.3M -77.5% | $10.0M +294.8% | $2.5M | $4.9B | $4.8B | $4.7B |
| Net Margin | 74.1% +45.1pp | 29.0% -4.6pp | 33.6% -8.9pp | 42.5% -14.7pp | 57.3% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | $0 +185.7% | $0 +256.7% | $0 -77.4% | $0 +174.0% | $0 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | $0 +185.7% | $0 +366.7% | $0 -82.8% | $0 +174.0% | $0 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $43.9M +3.8% | $42.3M -70.6% | $143.9M +0.0% | $143.9M +43.9% | $100.0M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $43.9M +3.8% | $42.3M -77.5% | $187.8M +30.5% | $143.9M +43.9% | $100.0M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
KalVista Pharmaceuticals, Inc.
NASDAQ:KALV
$1.44B
Avanos Medical, Inc.
NYSE:AVNS
$1.17B
COMPASS Pathways plc
NASDAQ:CMPS
$1.16B
Talkspace, Inc.
NASDAQ:TALK
$872.74M
Rigel Pharmaceuticals, Inc.
NASDAQ:RIGL
$607.79M
AngioDynamics, Inc.
NASDAQ:ANGO
$499.96M
Community Health Systems, Inc.
NYSE:CYH
$439.66M
ClearPoint Neuro, Inc.
NASDAQ:CLPT
$403.06M
SNDL Inc.
NASDAQ:SNDL
$369.44M
Gossamer Bio, Inc.
GOSS
$38.00M
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does NNNN generate?
Anbio Biotechnology Class A Ordinary Shares (NNNN) reported $9.76M of revenue in fiscal 2025.
Is NNNN profitable?
Anbio Biotechnology Class A Ordinary Shares (NNNN) reported $7.23M of net income, with a net margin of 74.1%.
Explore More
Continue the stock analysis
Jump to another research area for this company.